RareCyte announces new Synaptophysin CTC assay for blood-based characterization of treatment-resistant malignanciesSeattle, WA, June 01, 2021 – RareCyte® announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.
RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancerSeattle, WA, August 26, 2020 – RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.
RareCyte® announces the Orion™ spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysisSeattle, WA. July 16, 2020 – RareCyte, Inc., a company focused on providing Precision Biology™ solutions for life sciences, announced today the Orion spatial biology analysis platform applicable to translational and clinical research. Orion is based on a patented and proprietary technology that will accelerate immuno-oncology and infectious disease research. Orion enables comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment in a matter of hours, in contrast to existing technologies that require several days to weeks.
Accurate Spike-in of Circulating Tumor Cells into Blood Samples is Essential for Reliable Analysis in Oncology ApplicationsBerlin, Germany, Lyon, France, and Seattle, WA, USA, June 22, 2020: SCIENION AG and RareCyte Inc. today announced that cellenONE® proved to be a most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENION’s French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.
RareCyte webinar series 15 Sept 2021
Join Eric Kaldjian, MD, our Chief Medical Officer on September 15th as he presents “Resolving the Complexity of Tissue Immune Response with Orion High-Dimensional Imaging”. This talk will describe the application of 17-plex immuno-oncology fluorescence panel and H & E images on the same tissue sections, all in a single scan, single stain process.
RareCyte webinar series June 08 2021 available on demand
CTC analysis via liquid biopsy (blood) allows for a less-invasive method to identify cancer cells and can prove helpful in prognosis, treatment selection, patient stratification, and patient monitoring. Our two distinguished speakers, with over 50 years of combined experience in the field, will walk through these applications and supporting data.